• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三聚体融合前HIV-1包膜糖蛋白的结构与免疫识别

Structure and immune recognition of trimeric pre-fusion HIV-1 Env.

作者信息

Pancera Marie, Zhou Tongqing, Druz Aliaksandr, Georgiev Ivelin S, Soto Cinque, Gorman Jason, Huang Jinghe, Acharya Priyamvada, Chuang Gwo-Yu, Ofek Gilad, Stewart-Jones Guillaume B E, Stuckey Jonathan, Bailer Robert T, Joyce M Gordon, Louder Mark K, Tumba Nancy, Yang Yongping, Zhang Baoshan, Cohen Myron S, Haynes Barton F, Mascola John R, Morris Lynn, Munro James B, Blanchard Scott C, Mothes Walther, Connors Mark, Kwong Peter D

机构信息

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

HIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

Nature. 2014 Oct 23;514(7523):455-61. doi: 10.1038/nature13808. Epub 2014 Oct 8.

DOI:10.1038/nature13808
PMID:25296255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4348022/
Abstract

The human immunodeficiency virus type 1 (HIV-1) envelope (Env) spike, comprising three gp120 and three gp41 subunits, is a conformational machine that facilitates HIV-1 entry by rearranging from a mature unliganded state, through receptor-bound intermediates, to a post-fusion state. As the sole viral antigen on the HIV-1 virion surface, Env is both the target of neutralizing antibodies and a focus of vaccine efforts. Here we report the structure at 3.5 Å resolution for an HIV-1 Env trimer captured in a mature closed state by antibodies PGT122 and 35O22. This structure reveals the pre-fusion conformation of gp41, indicates rearrangements needed for fusion activation, and defines parameters of immune evasion and immune recognition. Pre-fusion gp41 encircles amino- and carboxy-terminal strands of gp120 with four helices that form a membrane-proximal collar, fastened by insertion of a fusion peptide-proximal methionine into a gp41-tryptophan clasp. Spike rearrangements required for entry involve opening the clasp and expelling the termini. N-linked glycosylation and sequence-variable regions cover the pre-fusion closed spike; we used chronic cohorts to map the prevalence and location of effective HIV-1-neutralizing responses, which were distinguished by their recognition of N-linked glycan and tolerance for epitope-sequence variation.

摘要

1型人类免疫缺陷病毒(HIV-1)包膜(Env)刺突由三个gp120和三个gp41亚基组成,是一种构象机器,通过从成熟的未结合配体状态,经受体结合中间体,重排为融合后状态来促进HIV-1进入。作为HIV-1病毒粒子表面唯一的病毒抗原,Env既是中和抗体的靶点,也是疫苗研发的重点。在此,我们报告了通过抗体PGT122和35O22捕获的处于成熟封闭状态的HIV-1 Env三聚体的3.5埃分辨率结构。该结构揭示了gp41的融合前构象,表明了融合激活所需的重排,并定义了免疫逃逸和免疫识别的参数。融合前的gp41通过四个螺旋环绕gp120的氨基末端和羧基末端链,形成一个膜近端环,通过将融合肽近端的甲硫氨酸插入gp41-色氨酸扣中来固定。进入所需的刺突重排包括打开扣并排出末端。N-连接糖基化和序列可变区覆盖融合前的封闭刺突;我们利用慢性感染队列绘制了有效的HIV-1中和反应的流行率和位置,这些反应通过其对N-连接聚糖的识别和对表位序列变异的耐受性来区分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/ec0ae0f678bc/nihms-625266-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/aa83dafd7095/nihms-625266-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/7b079c2a34b5/nihms-625266-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/39ac81a20371/nihms-625266-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/f709c793c960/nihms-625266-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/4f774b6a9198/nihms-625266-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/e78e82139d92/nihms-625266-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/5f1cc467a86b/nihms-625266-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/8f60e1f4f2dc/nihms-625266-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/ef14348d51e8/nihms-625266-f0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/ac12f274f893/nihms-625266-f0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/4ad8c38f6300/nihms-625266-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/645414701685/nihms-625266-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/8a3f13597ab8/nihms-625266-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/ecbc0e04be85/nihms-625266-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/fed833bd60c3/nihms-625266-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/ec0ae0f678bc/nihms-625266-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/aa83dafd7095/nihms-625266-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/7b079c2a34b5/nihms-625266-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/39ac81a20371/nihms-625266-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/f709c793c960/nihms-625266-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/4f774b6a9198/nihms-625266-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/e78e82139d92/nihms-625266-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/5f1cc467a86b/nihms-625266-f0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/8f60e1f4f2dc/nihms-625266-f0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/ef14348d51e8/nihms-625266-f0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/ac12f274f893/nihms-625266-f0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/4ad8c38f6300/nihms-625266-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/645414701685/nihms-625266-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/8a3f13597ab8/nihms-625266-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/ecbc0e04be85/nihms-625266-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/fed833bd60c3/nihms-625266-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0f2/4348022/ec0ae0f678bc/nihms-625266-f0006.jpg

相似文献

1
Structure and immune recognition of trimeric pre-fusion HIV-1 Env.三聚体融合前HIV-1包膜糖蛋白的结构与免疫识别
Nature. 2014 Oct 23;514(7523):455-61. doi: 10.1038/nature13808. Epub 2014 Oct 8.
2
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.一种通过病毒逃逸导致膜近端外部区域(MPER)暴露的新型HIV-1 gp120-gp41界面抗体的结构与识别
PLoS Pathog. 2017 Jan 11;13(1):e1006074. doi: 10.1371/journal.ppat.1006074. eCollection 2017 Jan.
3
Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.相邻 gp120 可变区 1 (V1) N-糖基化与中和敏感性相关,对 HIV-1 gp120-gp41 结合部位的变构调节。
PLoS Pathog. 2013;9(4):e1003218. doi: 10.1371/journal.ppat.1003218. Epub 2013 Apr 4.
4
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.基于11种Env三聚体的HIV-1包膜糖蛋白生产的糖基化基准图谱。
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.02428-16. Print 2017 May 1.
5
Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation.糖基化或 gp41 融合肽近端区的改变调节人类免疫缺陷病毒 (HIV-1) 包膜糖蛋白预触发构象的稳定性。
J Virol. 2023 Sep 28;97(9):e0059223. doi: 10.1128/jvi.00592-23. Epub 2023 Sep 11.
6
Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer.可溶性、未切割的HIV-1包膜三聚体的构象状态
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.00175-17. Print 2017 May 15.
7
Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers.裂解的、可溶性 HIV-1 包膜糖蛋白三聚体的结构特征。
J Virol. 2013 Sep;87(17):9865-72. doi: 10.1128/JVI.01222-13. Epub 2013 Jul 3.
8
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.一种结合gp41-gp120界面的人源抗体对HIV-1具有广泛且强效的中和作用。
Nature. 2014 Nov 6;515(7525):138-42. doi: 10.1038/nature13601. Epub 2014 Sep 3.
9
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.作为中和抗体易损位点的HIV-1融合肽。
Science. 2016 May 13;352(6287):828-33. doi: 10.1126/science.aae0474.
10
Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.I559P gp41变化对人类免疫缺陷病毒(HIV-1)膜包膜糖蛋白三聚体构象和功能的影响。
PLoS One. 2015 Apr 7;10(4):e0122111. doi: 10.1371/journal.pone.0122111. eCollection 2015.

引用本文的文献

1
Selection of Cyclized, Glycosylated Peptide Antigens That Tightly Bind HIV High Mannose Patch Antibodies.紧密结合HIV高甘露糖补丁抗体的环化糖基化肽抗原的筛选
ACS Cent Sci. 2025 Jun 12;11(7):1122-1134. doi: 10.1021/acscentsci.5c00539. eCollection 2025 Jul 23.
2
The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies.人类免疫缺陷病毒1型包膜糖蛋白:结构、功能及与中和抗体的相互作用
Nat Rev Microbiol. 2025 Jul 23. doi: 10.1038/s41579-025-01206-6.
3
Virus glycoprotein nanodisc platform for vaccine design.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.振荡模式下收集的X射线衍射数据的处理。
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
CD4-induced activation in a soluble HIV-1 Env trimer.可溶性HIV-1包膜三聚体中CD4诱导的激活。
Structure. 2014 Jul 8;22(7):974-84. doi: 10.1016/j.str.2014.05.001. Epub 2014 Jun 12.
3
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.
用于疫苗设计的病毒糖蛋白纳米盘平台
bioRxiv. 2025 Jun 16:2025.05.02.651272. doi: 10.1101/2025.05.02.651272.
4
Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques.短暂的聚糖屏蔽减少在感染SHIV的猕猴中诱导出结合CD4位点的广谱中和抗体。
Cell Rep. 2025 Jun 24;44(6):115848. doi: 10.1016/j.celrep.2025.115848. Epub 2025 Jun 13.
5
Detection of Protein Interactions and Dynamics During Viral Infection via Fluorescence Resonance Energy Transfer.通过荧光共振能量转移检测病毒感染过程中的蛋白质相互作用和动态变化
Methods Mol Biol. 2025;2940:387-398. doi: 10.1007/978-1-0716-4615-1_34.
6
Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site.可溶性CD4通过靶向内体受体结合位点抑制埃博拉病毒感染。
iScience. 2025 May 2;28(6):112573. doi: 10.1016/j.isci.2025.112573. eCollection 2025 Jun 20.
7
Current progress and challenges in the design and development of a successful COVID-19 vaccine.成功研发新冠疫苗过程中的当前进展与挑战
Fundam Res. 2021 Mar;1(2):139-150. doi: 10.1016/j.fmre.2021.01.011. Epub 2021 Jan 26.
8
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning.一种通过双特异性抗体介导的预定位作用具有增强的HIV-1中和能力的广谱抗体。
Nat Commun. 2025 May 18;16(1):4617. doi: 10.1038/s41467-025-60035-6.
9
Conformational trajectory of the HIV-1 fusion peptide during CD4-induced envelope opening.HIV-1融合肽在CD4诱导包膜开放过程中的构象轨迹。
Nat Commun. 2025 May 17;16(1):4595. doi: 10.1038/s41467-025-59721-2.
10
Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimer.对非人类灵长类动物进行疫苗接种可引发一种广泛中和抗体谱系,该谱系靶向HIV-1包膜三聚体上的一个四级表位。
Immunity. 2025 Jun 10;58(6):1598-1613.e8. doi: 10.1016/j.immuni.2025.04.010. Epub 2025 May 7.
中和抗体与非中和抗体对天然样可溶性HIV-1包膜三聚体、未切割的包膜蛋白和单体亚基的差异结合。
Retrovirology. 2014 May 29;11:41. doi: 10.1186/1742-4690-11-41.
4
Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.在完整的 HIV-1 Env 三聚体上,gp41-gp120 界面处的一个四分体、依赖裂解的表位的结构描绘。
Immunity. 2014 May 15;40(5):669-80. doi: 10.1016/j.immuni.2014.04.008. Epub 2014 Apr 24.
5
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers.广谱中和 HIV 抗体定义了 gp41 融合前构象上糖依赖性表位在裂解包膜三聚体上。
Immunity. 2014 May 15;40(5):657-68. doi: 10.1016/j.immuni.2014.04.009. Epub 2014 Apr 24.
6
Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.抗体8ANC195揭示了HIV-1包膜刺突上一个广泛易损位点。
Cell Rep. 2014 May 8;7(3):785-95. doi: 10.1016/j.celrep.2014.04.001. Epub 2014 Apr 24.
7
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.V1V2 定向 HIV 中和抗体的产生途径。
Nature. 2014 May 1;509(7498):55-62. doi: 10.1038/nature13036. Epub 2014 Mar 2.
8
Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity.HIV-1 gp120 第二可变环 (V2) 中的酪氨酸硫酸化稳定了 V2-V3 相互作用,并调节了中和敏感性。
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3152-7. doi: 10.1073/pnas.1314718111. Epub 2014 Feb 3.
9
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.慢性HIV-1感染期间广泛中和抗体反应的流行率。
AIDS. 2014 Jan 14;28(2):163-9. doi: 10.1097/QAD.0000000000000106.
10
A common solution to group 2 influenza virus neutralization.针对 2 型流感病毒的中和作用的常见解决方案。
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):445-50. doi: 10.1073/pnas.1319058110. Epub 2013 Dec 11.